Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORL-4-500 in Advanced Cancer
NCT06005740Phase 1Active, not recruiting
- Sponsor
- TORL BioTherapeutics
- Start
- Dec 2023
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of torl-4-500 in solid tumor, hepatocellular carcinoma (HCC) and adrenocortical carcinoma (ACC) (2 arms), sponsored by TORL BioTherapeutics. Primary endpoints: Incidence and severity of adverse events and serious adverse events at 2 years, Maximum Tolerated Dose at 28 days and 1 more. Started Dec 2023; status: active, not recruiting.
02
Drugs
torl-4-500
03
Conditions
solid tumorhepatocellular carcinoma (HCC)adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT06005740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005740.